Kathryn Romano sold $131k of KRYS
Chief Accounting Officer at Krystal Biotech, Inc.. 750 shares at an average of $175.22, traded Feb 27, 2025, filed Feb 28, 2025.
Score components
- +15RoleOfficer
- +11Trade size$131k at market
- 0Share of holdings soldSold 5.6% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001801385-25-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 26, 2025 | FTax withholding Common Stock10b5-1 | -2,268 | $176.39 | $400k | 13,354 | Feb 28, 2025 |
| Feb 27, 2025 | SOpen-market sale Common Stock10b5-1 | -750 | $175.22 | $131k | 12,604 | Feb 28, 2025 |
| Feb 28, 2025 | MOption exercise Common Stock10b5-1 | +5,000 | $0.00 | $0 | 17,604 | Feb 28, 2025 |
| Feb 28, 2025 | FTax withholding Common Stock10b5-1 | -2,315 | $179.25 | $415k | 15,289 | Feb 28, 2025 |
| Feb 28, 2025 | MOption exercise Common Stock10b5-1 | +7,500 | $0.00 | $0 | 22,789 | Feb 28, 2025 |
| Feb 28, 2025 | FTax withholding Common Stock10b5-1 | -3,471 | $179.25 | $622k | 19,318 | Feb 28, 2025 |
| Feb 28, 2025 | MOption exercise Performance Stock Unitsderivative10b5-1 | -5,000 | $0.00 | $0 | 0 | Feb 28, 2025 |
| Feb 28, 2025 | MOption exercise Performance Stock Unitsderivative10b5-1 | -7,500 | $0.00 | $0 | 7,500 | Feb 28, 2025 |
| Feb 28, 2025 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +10,000 | $0.00 | $0 | 10,000 | Feb 28, 2025 |
| Feb 28, 2025 | AGrant or award Restricted Stock Unitsderivative10b5-1 | +2,200 | $0.00 | $0 | 2,200 | Feb 28, 2025 |
Related signals
Other insiders at Krystal Biotech, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $9.0M 25,000 shares | -2% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $9.0M 25,000 shares | -2% | |
| 45Moderate | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $8.9M 50,000 shares | -3% | |
| 40Moderate | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $8.9M 50,000 shares | -3% | |
| 38Weak | Krystal Biotech, Inc. | Krish S Krishnan President and CEO | $8.2M 50,000 shares | -3% | |
| 33Weak | Krystal Biotech, Inc. | Suma Krishnan President, R&D | $8.2M 50,000 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.